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Abstract
Purpose Patients with Graves’ orbitopathy can present with asymmetric disease. The aim of this study was to identify clini-
cal characteristics that distinguish asymmetric from unilateral and symmetric Graves’ orbitopathy.
Methods This was a multi-centre study of new referrals to 13 European Group on Graves’ Orbitopathy (EUGOGO) tertiary 
centres. New patients presenting over a 4 month period with a diagnosis of Graves’ orbitopathy were included. Patient demo-
graphics were collected and a clinical examination was performed based on a previously published protocol. Patients were 
categorized as having asymmetric, symmetric, and unilateral Graves’ orbitopathy. The distribution of clinical characteristics 
among the three groups was documented.
Results The asymmetric group (n = 83), was older than the symmetric (n = 157) group [mean age 50.9 years (SD 13.9) vs 
45.8 (SD 13.5), p = 0.019], had a lower female to male ratio than the symmetric and unilateral (n = 29) groups (1.6 vs 5.0 vs 
8.7, p < 0.001), had more active disease than the symmetric and unilateral groups [mean linical Activity Score 3.0 (SD 1.6) 
vs 1.7 (SD 1.7), p < 0.001 vs 1.3 (SD 1.4), p < 0.001] and significantly more severe disease than the symmetric and unilat-
eral groups, as measured by the Total Eye Score [mean 8.8 (SD 6.6) vs 5.3 (SD 4.4), p < 0.001, vs 2.7 (SD 2.1), p < 0.001].
Conclusion Older age, lower female to male ratio, more severe, and more active disease cluster around asymmetric Graves’ 
orbitopathy. Asymmetry appears to be a marker of more severe and more active disease than other presentations. This simple 
clinical parameter present at first presentation to tertiary centres may be valuable to clinicians who manage such patients.
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Introduction
Graves’ orbitopathy (GO) is an orbital disorder closely 
associated with autoimmune thyroid disease [1]. GO is 
responsible for considerable psychosocial morbidity, per-
sonal and societal cost [2, 3], can rarely cause blindness 
[4], and is associated with increased mortality including 
that from suicide [5, 6]. Most patients present with bilat-
eral disease though asymmetric or unilateral disease is 
also observed in a minority of cases. The prevalence of 
unilateral disease is 4.5–14% [7–11], while asymmetric 
disease is reported to occur in 9–34% of patients with GO 
[9–12]. Although the underlying pathogenesis of all forms 
of GO is likely to be the same and based on autoimmunity, 
asymmetric and unilateral GO may differ in the relative 
contributions of mechanical and inflammatory influences 
as well as local vascular or anatomical factors. The objec-
tive of this study was to analyze data from a prospec-
tive cross-sectional multi-centre study [13] and identify 
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clinical characteristics that distinguish asymmetric, uni-
lateral and bilateral symmetric GO.
Methods
Patients
All new referrals of patients with a diagnosis of GO to 
EUGOGO centres were recruited prospectively during 
a 4-month period between 1st September 2012 and 31st 
December 2012. Data were collected during their first con-
sultation as described in Perros et al. [13].
Assessments
Ophthalmic signs were assessed according to established 
EUGOGO protocols [13]. All assessors had received spe-
cialist training in the clinical evaluation of patients with 
GO and had attended at least one EUGOGO teaching 
course. Detailed description of assessments can be found 
in Perros et al. [13]. Unilateral disease was defined as one 
or more clinical features of GO in one eye without any 
evidence of GO in the contralateral eye. Asymmetric GO 
was defined as disease present in both eyes with one or 
more of the following features: difference between the two 
eyes in exophthalmometer readings by two or more mm; 
difference in palpebral aperture by two or more millim-
eter, difference in eyelid swelling by one or more grades; 
difference in eyelid erythema by one or more grades; dif-
ference in conjunctival redness by one or more grades; 
presence of dysthyroid optic neuropathy in one eye only. 
Duration of GO was ascertained based on the patient’s his-
tory. This study was observational to aid audit and service 
development by EUGOGO centres, and ethical committee 
approval was deemed not to be necessary [13]. Confidenti-
ality was preserved by pseudoanonymizing the data (pseu-
donymization substitutes the identity of the data subject 
in such a way that additional information is required to re-
identify the data subject). The described research adhered 
to the tenets of the Declaration of Helsinki.
Statistical analyses
To compare clinical characteristics, group linear model 
ANOVA was used [14]. Pearson Chi-square tests or Fish-
er’s exact test and trend test for ordinal variables were 
used where appropriate. The software “R” was used for 
statistical analysis.
Results
There were 269 patients with a diagnosis of GO of whom 
157 had symmetric (58.4%), 83 asymmetric (30.9%) and 29 
(10.7%) unilateral disease. Although there was an overall 
slight excess of higher right sided exophthalmometer read-
ings, the differences in distribution of exophthalmos meas-
urements between right and left for the entire group, within 
and between groups, were not statistically significant. The 
baseline characteristics of patients are shown in Table 1. 
Comparisons between groups showed that the asymmetric 
group had an older age than the symmetric group [mean age 
50.9 years (SD 13.9) vs 45.8 (SD 13.5), p = 0.019], lower 
female to male ratio than the other two groups (1.6 vs 5.0 vs 
8.7, p < 0.001), had more active disease than the symmetric 
and unilateral groups [mean Clinical Activity Score 3.0 (SD 
Table 1  Clinical characteristics of patients
CAS clinical activity score, TES total eye score, PA palpebral aper-
ture, GO Graves’ orbitopathy
a Mean (standard deviation); bworse TES of the two eyes
Symmetric Asymmetric Unilateral
% (No.) 58.4 (157) 30.9 (83) 10.8 (29)
Age [years, mean (SD)] 45.8 (13.5) 50.9 (13.9) 48.6 (15.2)
Female [% (No.)] 83.4 (130) 61.4 (74) 89.7 (26)
Nation [% (No.)]
 Belgium 3.8 (6) 7.2 (6) 3.4 (1)
 Denmark 2.5 (4) 0 (0) 6.9 (2)
 France 10.8 (17) 16.9 (14) 20.7 (6)
 Germany 24.2 (38) 27.7 (23) 27.6 (8)
 Italy 30.6 (48) 31.3 (26) 13.8 (4)
 Serbia 6.4 (10) 8.4 (7) 0 (0)
 Switzerland 7 (11) 1.2 (1) 6.9 (2)
 Turkey 5.1 (8) 3.6 (3) 13.8 (4)
 UK 9.6 (15) 3.6 (3) 6.9 (2)
Previous thyroid treatment [% (No.)]
 Radioiodine 17.2 (27) 15.7 (13) 24.1 (7)
 Thyroidectomy 22.3 (35) 22.9 (19) 17.2 (5)
 Anti-thyroid drugs 43.9 (69) 43.4 (36) 41.4 (12)
 No treatment 16.6 (26) 18.1 (15) 17.2 (5)
CAS [mean (SD)]a 1.7 (1.7) 3.0 (1.6) 1.3 (1.4)
TES [mean (SD)]a,b 5.3 (4.4) 8.8 (6.6) 2.7 (2.2)
Difference in exophthal-
mos between right and 
left  eyea [mm, mean 
(SD)]
0.5 (5) 2.5 (1.6) 2.2 (2.2)
Difference in PA between 
right and left  eyea [mm, 
mean (SD)]
1.1 (1.4) 1.7 (1.6) 2.1 (1.6)
Current smoker (No. %) 62 (39.5) 29 (39.8) 13 (44.8)
Duration of  GOa (months) 27.8 (46.1) 43.2 (98.7) 22.7 (38.8)
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1.6) vs 1.7 (SD 1.7), p < 0.001 vs 1.3 (SD 1.4), p < 0.001] 
and significantly more severe disease than the symmetric 
and unilateral groups, as measured by the Total Eye Score 
[mean 8.8 (SD 6.6) vs 5.3 (SD 4.4), p < 0.001, vs 2.7 (SD 
2.1), p < 0.001]. The unilateral group had less severe disease 
than either of the other two groups (p < 0.001) (Table 2). 
There were no significant differences in all other clinical 
characteristics (country of origin, type of underlying thyroid 
disease, type of treatment for thyroid disease, time since 
diagnosis of thyroid disease, duration of GO, coexistent dia-
betes, family history of thyroid disease, family history of 
autoimmune disease, smoking). Thus, the asymmetric group 
emerged as the most distinct compared with the others, with 
an older mean age, lowest female to male ratio, more active 
and more severe GO. Pooling the asymmetric and unilateral 
groups together and comparing them with the symmetric 
group did not alter the above findings.
Discussion
Facial asymmetry is important as it can be a cause of 
distress to patients [15], including a negative impact on 
the quality of life in patients with asymmetric GO [16]. 
Asymmetry is also an intriguing observation in diseases 
that are thought to be systemic, and further study may pro-
vide insights into factors that modulate disease expression. 
Asymmetrical or unilateral GO may precede bilateral dis-
ease in some patients [11, 17], a fact that is of importance 
in timing of interventions such as rehabilitative surgery. 
Asymmetry in the anatomy of the bony orbit, optic canal, 
ophthalmic vessels, length of the globe, and exophthal-
mometer readings of normal subjects is common [18–20], 
but whether structural variations in the orbits are more 
pronounced in patients with asymmetric/unilateral GO is 
unknown. The prevalence of asymmetric disease in our 
cohort was 30.9% and that of unilateral disease 10.7%, 
which is comparable to reports in published literature of 
asymmetric in 9–34% [9, 10, 12, 16, 17, 22] and unilat-
eral disease in 4.5–14.0% of patients with GO [7–11]. The 
variations in the above figures between studies are prob-
ably due to differences in definitions of asymmetry and 
unilaterality used, and inter-/intra-observer variation. In 
addition, differences in the phase of the natural history of 
GO at the time of assessment may also have contributed, 
as after the passage of time some patients with unilateral 
disease develop bilateral features [11, 17]. An associa-
tion between asymmetric disease and older age [22, 23], 
more active disease [22], and lower female to male ratio 
[24], has been previously reported, and our study has con-
firmed these associations. The clustering of all the above 
features as well as increased severity around asymmetric 
GO is a finding that has not been described before. The 
reason why asymmetry should be associated with older 
age and a lower female to male ratio is unclear, though 
an association between older age and male gender with 
more severe disease has been previously observed [23–25] 
and may be partly explained by differences in exposure 
to smoking. The data from this study however, suggest 
that smoking is an unlikely explanation for this cohort 
as the rates of smoking were very similar between the 
asymmetric and symmetric groups and highest in the uni-
lateral group, though the differences were not statistically 
significant (Table 1). This study also showed that patients 
with unilateral disease have significantly milder GO than 
symmetric or asymmetric variants. Possible explanations 
for this observation include the fact that patients with uni-
lateral mild GO are more likely to be referred to tertiary 
centres than bilateral or asymmetric GO of similar sever-
ity, for exclusion of other diagnoses, in accordance with 
published guidelines [26], as well as the association of 
unilateral disease with euthyroidism and low TSH recep-
tor antibodies [27]. The explanation for why asymmet-
ric/unilateral disease occurs, may partly lie in underlying 
asymmetry of the bony orbit, which is a normal finding 
in all people [19] as discussed above, however additional 
contributors are likely to play a role. A previous study 
tested the hypothesis that sleeping position may be respon-
sible, but no such association was found [12]. It is possi-
ble that differences in vascularity between orbits may be 
at play, although this has not been studied specifically in 
asymmetric disease. However, differences in arterial and 
venous flow in orbital vessels in patients with and with-
out GO have been described, as well as in patients with 
and without dysthyroid optic neuropathy [28]. Other local 
factors relating to anatomy and properties of soft tissues 
(e.g. of the elasticity of the orbital septae), asymmetri-
cal distribution of resident inflammatory cells in the orbit 
and molecular differences in potential for adipogenesis 
and production of proinflammatory cytokines by orbital 
Table 2  Statistically significant differences between the three groups
CAS clinical activity score, TES total eye score
a asymmetric vs symmetric p = 0.019; basymmetric vs symmetric 
and asymmetric vs unilateral, p < 0.001; casymmetric vs symmetric 
and asymmetric vs unilateral, p < 0.001; dasymmetric vs symmetric 
and asymmetric vs unilateral, p < 0.001; eunilateral vs symmetric, 
p < 0.001
Symmetric Asymmetric Unilateral
No. (%) 157 (58.4) 83 (30.9) 29 (10.8)
Age [years, mean (SD)]a 45.8 (13.5) 50.9 (13.9) 48.6 (15.2)
Female (No. %)b 130 (83.4) 74 (61.4) 26 (89.7)
CAS [mean (SD)]c 1.7 (1.7) 3.0 (1.6) 1.3 (1.4)
TES [mean (SD)]d,e 5.3 (4.4) 8.8 (6.6) 2.7 (2.2)
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tissues, and unilateral triggers such as infection, may also 
contribute. The natural history of asymmetric and unilat-
eral disease is not well studied, but the available evidence 
suggests that in a significant proportion of patients with 
unilateral disease (14–36%), bilaterality eventually ensues 
in due course [11,17], so the natural course of the disease 
in one orbit may lag behind the other. The strengths of 
our study were the large number of patients included, its 
multi-centre and multi-national design, clinical assess-
ments based on well-defined protocols, and prospective 
recruitment over a 4 month period simultaneously by all 
centres. Weaknesses included absence of detailed motil-
ity data (other than Gorman score), potential errors due to 
multiple observer variation, lack of imaging studies and 
absence of longitudinal follow-up data, which is crucial 
in understanding how these subtypes of GO inter-relate, 
progress from one to another and, most importantly, how 
do they respond to therapy. The management of GO can be 
difficult and it is recommended that all but the mildest of 
cases are referred to tertiary centres [26]. It is not known 
whether early intervention diminishes the risk or incidence 
of asymmetric disease, or whether the ultimate prognosis 
is worse than other phenotypes in terms of disease sever-
ity, and associated psycho-social burden, although a nega-
tive association with quality of life has been reported [16]. 
Nonetheless, medical treatments are most effective during 
the active phase of the disease and recognizing and focus-
ing resources during this window is important. Our data 
suggest that asymmetry may be a marker of greater disease 
activity and severity, which can be a useful indicator for 
prioritizing cases when referrals are received by tertiary 
centres. In conclusion, this study has shown that asymmet-
ric GO is associated with older age, a lower female to male 
ratio, more active and more severe disease than symmetric 
or unilateral GO. Clinicians who manage patients with GO 
should be aware that patients with asymmetric GO have 
more active and more severe disease.
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